RedHill Biopharma Ltd. (RDHL)
Automate Your Wheel Strategy on RDHL
With Tiblio's Option Bot, you can configure your own wheel strategy including RDHL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RDHL
- Rev/Share 0.0007
- Book/Share -0.0004
- PB -4683.8444
- Debt/Equity -0.076
- CurrentRatio 0.536
- ROIC 3.8184
- MktCap 4078966.0
- FreeCF/Share -0.0008
- PFCF -0.435
- PE -2652.9322
- Debt/Assets 0.0197
- DivYield 0
- ROE 6.3259
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102 [1] to Hyloris (Euronext Brussels: HYL) in a potential $60 million plus royalties deal Initiation of the Bayer-funded Phase 2 clinical study of opaganib [2] in combination with Bayer's (ETR: BAYN) darolutamide in advanced prostate cancer Status of the U.S. government-supported pipeline programs and expected 2025 catalysts Significant commercial progress with Talicia®: Additional marketing authorization applications in new markets being evaluated Discussions ongoing focused on significant cost of goods (COGs) reduction Inclusion as first-line …
Read More
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and commercialize RHB-102 (Bekinda®) across all indications and territories outside the United States, Canada and Mexico - Recent positive UK MHRA advice provided a clear pathway for a UK Marketing Authorization Application (MAA). If approved, RHB-102 could be the first oral 24-hour extended-release ondansetron for the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) - RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if …
Read More
About RedHill Biopharma Ltd. (RDHL)
- IPO Date 2013-01-07
- Website https://www.redhillbio.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Dror Ben-Asher
- Employees 35